Journal of surgical oncology · 2015
Prognostic factors for low rectal cancer patients undergoing intersphincteric resection after neoadjuvant chemoradiation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Soo Young, Jo Jeong Seon, Kim Hun Jin, Kim Chang Hyun, Kim Young Jin, Kim Hyeong Rok
Аннотация
OBJECTIVES: This study aimed to investigate prognostic factors for low rectal cancer patients undergoing intersphincteric resection (ISR) following neoadjuvant chemoradiation (CRT).
METHODS: We retrospectively reviewed 163 primary rectal cancer patients without distant metastasis who underwent ISR following neoadjuvant CRT between January 2006 and December 2011. Prognostic factors for disease-free survival (DFS) and local recurrence-free survival (LRFS) were evaluated.
RESULTS: The median follow-up period was 53 months (range, 0-82 months). Kaplan-Meier survival analysis indicated different 3-year DFS (stage 0, 96.2%; I, 84.8%; II, 72.9%; III, 38.0%) and 3-year LRFS (stage 0, 100.0%; I, 92.4%; II, 91.1%; III, 70.9%) according to pathologic TNM stages, particularly stage III. Multivariable Cox regression analysis suggested that DFS was associated with ypT (3/4 vs. 0/1/2) and ypN (1/2 vs. 0) stages, whereas LRFS with ypN stage (1/2 vs. 0), tumor size (≥3.5 cm vs. <3.5 cm), and tumor height from the anal verge (≤2 cm vs. >2 cm).
CONCLUSIONS: ISR following CRT could be feasible in stage-I and II low rectal cancer patients, but might be related to poor oncologic outcomes in those with stage-III disease. The indication for ISR or abdominoperineal resection should be carefully evaluated in cases of low rectal cancer with suspicious lymph node metastasis after CRT.
METHODS: We retrospectively reviewed 163 primary rectal cancer patients without distant metastasis who underwent ISR following neoadjuvant CRT between January 2006 and December 2011. Prognostic factors for disease-free survival (DFS) and local recurrence-free survival (LRFS) were evaluated.
RESULTS: The median follow-up period was 53 months (range, 0-82 months). Kaplan-Meier survival analysis indicated different 3-year DFS (stage 0, 96.2%; I, 84.8%; II, 72.9%; III, 38.0%) and 3-year LRFS (stage 0, 100.0%; I, 92.4%; II, 91.1%; III, 70.9%) according to pathologic TNM stages, particularly stage III. Multivariable Cox regression analysis suggested that DFS was associated with ypT (3/4 vs. 0/1/2) and ypN (1/2 vs. 0) stages, whereas LRFS with ypN stage (1/2 vs. 0), tumor size (≥3.5 cm vs. <3.5 cm), and tumor height from the anal verge (≤2 cm vs. >2 cm).
CONCLUSIONS: ISR following CRT could be feasible in stage-I and II low rectal cancer patients, but might be related to poor oncologic outcomes in those with stage-III disease. The indication for ISR or abdominoperineal resection should be carefully evaluated in cases of low rectal cancer with suspicious lymph node metastasis after CRT.